One in Six Billion podcast

A podcast about diabetes and genes

With Andrew Hattersley
and Maggie Shepherd

Series 3 episode 5 Andrew Lotery and Amanda Stride: Glucokinase MODY – a mildly raised fasting glucose for life that should not be treated

Posted by Design Studio

Released 27 November 2024
In this episode we talk to Andrew Lotery about how he was found to have a raised fasting glucose on an insurance medical. He was treated as Type 2 diabetes but he questioned this as he was young. slim and physically fit. A chance reading of a research funder’s newsletter led him to the Exeter team and a diagnosis of glucokinase MODY. Amanda Stride worked as a research registrar in Exeter. She showed that in glucokinase MODY the fasting glucose was raised from birth and remained stable and regulated throughout life with treatment not changing the blood glucose. Anna Steele showed in her PhD that patients with glucokinase MODY did not get complications affecting the eye or kidney even after 50 years of raised glucose. So in glucokinase MODY treatment with insulin or tablets is not needed and does not work; patients should be discharged and not followed up.

In this episode we talk to Andrew Lotery about how he was found to have a raised fasting glucose on an insurance medical. He was treated as Type 2 diabetes but he questioned this as he was young. slim and physically fit. A chance reading of a research funder’s newsletter led him to the Exeter team and a diagnosis of glucokinase MODY.  Amanda Stride worked as a research registrar in Exeter.  She showed that in glucokinase MODY the fasting glucose was raised from birth and remained stable and regulated throughout life with treatment not changing the blood glucose. Anna Steele showed in her PhD that patients with glucokinase MODY did not get complications affecting the eye or kidney even after 50 years of raised glucose.  So in glucokinase MODY treatment with insulin or tablets is not needed and does not work; patients should be discharged and not followed up.

Andrew Lotery works as a clinical research professor in ophthalmology in Southampton, UK.  In his 30s he was working in the USA and had an insurance medical that found he unexpectedly had a mildly raised fasting glucose even though he had no symptoms.  His doctors did not know if this was Type 1 or Type 2 diabetes. It did not progress rapidly to high glucose values, so the initial diagnosis of Type 1 was changed to Type 2.  However he was slim and very physically fit, which is unusual for young-onset Type 2 diabetes.  He was given Metformin which did not alter his glucose.  Luckily, he read an article in the Wellcome Trust newsletter describing Andrew’ Hattersley’s research into glucokinase MODY ; recognising glucokinase MODY fitted his situation he emailed Andrew who arranged testing that confirmed he did have glucokinase MODY and not Type 2 diabetes.  He stopped his metformin which made no difference to his blood glucose.

Amanda Stride is a consultant endocrinologist in Torbay hospital in Devon.  Having trained in Birmingham she came to Exeter to work as a research registrar with Andrew, Sian and Maggie.  Her first research was to work with researchers across Europe looking at a range of different changes in the glucokinase gene in patients of different ages.  The main thing she found was that these genetic changes resulted in the fasting glucose being mildly raised (5.5-8.5 mmol/l) from birth and remaining relatively stable throughout life.   The glucose was regulated so when they drank a sugary drink the glucose went up but fell back again to close to the fasting level within 2 hours.  This result in glucokinase MODY was in marked contrast to HNF1A MODY where the fasting was not raised till aged 15-25 years and then progressively rose with age, and the glucose did not return to baseline after a glucose load.  This paper can be read here:

https://pubmed.ncbi.nlm.nih.gov/11914749/

Crucially Amanda went on to show that in glucokinase MODY that treatment did not affect the blood glucose so that HbA1c was unaltered when patients stopped their insulin or tablet treatment, This paper is here:

https://pmc.ncbi.nlm.nih.gov/articles/PMC3855531/pdf/125_2013_Article_3075.pdf

Anna Steele, when working as a research nurse doing a PhD in Exeter, showed that glucokinase MODY patients who had 50 years of untreated raised glucose did not get diabetes related problems affecting the eyes or the kidneys. This paper is her

https://jamanetwork.com/journals/jama/fullarticle/1814212

This research combined has supported that once diagnosed with glucokinase MODY patients do not need and do not respond to glucose lowering medication.  They should therefore be discharged from medical care.  Only family members already thought to have diabetes, prediabetes or gestational diabetes should be genetically tested as it gives them the opportunity to be diagnosed with glucokinase and medication stopped. The only time that glucokinase can have an impact on health outcomes is in pregnancy.  This will be covered in the next 2 episodes of the podcast.

Summaries about GCK (glucokinase)b  MODY for patients and their healthcare workers can be found on our website here https://www.diabetesgenes.org/what-is-mody/what-is-glucokinase-gck/

A good medical and scientific overview of glucokinase MODY and all the research done on it is this review article written by the Exeter team here

https://diabetesjournals.org/care/article/38/7/1383/30805/Recognition-and-Management-of-Individuals-With